Andere talen Sutro Biopharma, Inc.

Aandelen

STRO

US8693671021

Biotechnologie & Medisch Onderzoek

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 24-01-2025			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
2,040 ^USD	+0,49%		+1,49%	+10,87%

15/01	Sutro Biopharma, Inc. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-15-2025 02:15 PM
10/12	Sutro Biopharma kondigt geselecteerde dosis aan voor Luvelta en topresultaten van het dosisoptimalisatiegedeelte van de Reframe-O1-studie in platinaresistente eierstokkanker	CI

Andere talen

Sutro Biopharma and Boehringer Ingelheim BioXcellence collaboration, Established First-in-class Cell-free Capabilities at Commercial Scale	08/01
Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference	08/01
Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference	07/01
Sutro Biopharma and Boehringer Ingelheim BioXcellence™ collaboration: Established first-in-class cell-free capabilities at commercial scale	07/01
Sutro Biopharma, Inc.(NasdaqGM:STRO) added to NASDAQ Biotechnology Index	23/12
Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of REFRME-O1 Trial in Platinum Resistant Ovarian Cancer	11/12
Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of REFRαME-O1 Trial in Platinum Resistant Ovarian Cancer	10/12
Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of Reframe-O1 Trial in Platinum Resistant Ovarian Cancer	10/12
Sutro Biopharma : Reports Third Quarter 2024 Financial Results and Business Highlights Form 8 K	13/11
Sutro Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	13/11
Earnings Flash (STRO) SUTRO BIOPHARMA Posts Q3 Revenue $8.5M	13/11
Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights	13/11
Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference	04/11
Sutro Biopharma Announces Initiation of the Registration-enabling REFRME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML	04/11
Sutro Biopharma Opens Enrollment for Luveltamab Tazevibulin Trial	01/11
Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML	01/11
Sutro Biopharma, Inc. Announces Initiation of the Registration-Enabling REFRaME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML	01/11
Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum	10-10-24
Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-Term Pipeline At Research Forum	10-10-24
Sutro Biopharma Announces Inducement Grant under Nasdaq Listing Rule 5635(4)	23-09-24
Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	20-09-24
Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024	14-09-24
Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO2024	14-09-24
Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024	11-09-24
Sutro Biopharma Announces Initiation of REFRME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer	23-08-24

Word de lid om toegang te krijgen tot meer nieuws.

Gratis inschrijven

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Sutro Biopharma, Inc.

Aandelen

STRO

US8693671021

Biotechnologie & Medisch Onderzoek

Andere talen

Filters